2026-01-29 - Analysis Report
**Stock Summary: Johnson & Johnson (JNJ)**

### Overview
Johnson & Johnson is a multinational health care company that develops, manufactures, and sells a wide range of pharmaceutical, consumer health, and medical device products.

### Return Rate Comparison

| Stock | Return Rate |
| --- | --- |
| Review Stock (JNJ) | **80.57%** |
| Comparison Stock (VOO) | **128.51%** |

The divergence between the two stocks is **-47.90**, which means JNJ's cumulative return is lagging behind the S&P 500's by a significant margin.

### Alpha, Beta Analysis

| Period | CAGR | MDD | Alpha | Beta | Market Cap (B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | **9.0%** | **16.9%** | **0.0%** | **0.7** | $315.2B |
| 2017-2019 | **21.0%** | **16.9%** | **-4.0%** | **0.7** | $356.2B |
| 2018-2020 | **13.0%** | **25.9%** | **-11.0%** | **0.7** | $384.3B |
| 2019-2021 | **26.0%** | **25.9%** | **-38.0%** | **0.6** | $417.8B |
| 2020-2022 | **15.0%** | **25.9%** | **11.0%** | **0.5** | $431.4B |
| 2021-2023 | **-11.0%** | **14.1%** | **-29.0%** | **0.3** | $382.8B |
| 2022-2024 | **-23.0%** | **14.1%** | **-52.0%** | **0.2** | $353.2B |
| 2023-2025 | **37.0%** | **14.1%** | **-38.0%** | **0.1** | $505.4B |

### Recent Stock Price Fluctuations

| Moving Average | Value |
| --- | --- |
| 5-day SMA | **\$220.51** |
| 20-day SMA | **\$212.82** |
| 60-day SMA | **\$204.97** |
| Last Close | **\$224.44** |
| Last Market | **\$227.5** |

### RSI, PPO Index Indicators and Market Risk Indicator

| Indicator | Value |
| --- | --- |
| RSI | **83.91** |
| PPO | **0.42** |
| Market Risk Indicator (MRI) | **0.70** |

The MRI indicates a Medium risk level, and the RSI is overbought.

### Expected Return

- **-62.20%**: Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

### Recent News & Significant Events

Recent news headlines include:

* "Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?"
* "Morgan Stanley upgrades Johnson & Johnson, sees upside on robust drug pipeline"
* "Whittier Trust Co. Sells 5,888 Shares of Johnson & Johnson $JNJ"
* "J&J upgraded at Morgan Stanley on growth outlook (JNJ:NYSE)"
* "Johnson & Johnson Stock Forecast: Trending Bullish Among Analysts"

### Analyst Opinions

* **Analyst Consensus:** Buy
* **Mean (1=StrongBuy~5=Sell):** 2.16
* **Opinions:** 24
* **Target Price (avg/high/low):** 227.92 / 265.00 / 155.00

### Recent Earnings Analysis

| Date | EPS | Revenue (B$) |
| --- | --- | --- |
| 2025-10-22 | **2.14** | **23.99** |
| 2025-07-24 | **2.3** | **23.74** |
| 2025-04-23 | **4.57** | **21.89** |
| 2024-10-23 | **1.12** | **22.47** |
| 2025-10-22 | **1.12** | **22.47** |

### Financial Information: Revenue and Profitability

| Quarter | Revenue (B$) | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | **\$23.99B** | **69.56%** |
| 2025-06-30 | **\$23.74B** | **67.87%** |
| 2025-03-31 | **\$21.89B** | **66.40%** |
| 2024-12-31 | **\$22.52B** | **68.35%** |

### Financial Information: Capital and Profitability

| Quarter | Equity (B$) | ROE |
| --- | --- | --- |
| 2025-09-30 | **\$79.28B** | **6.50%** |
| 2025-06-30 | **\$78.47B** | **7.06%** |
| 2025-03-31 | **\$78.11B** | **14.08%** |
| 2024-12-31 | **\$71.49B** | **4.80%** |

### Comprehensive Analysis (Summary of previous items)

Overall, the stock is trading near its 60-day SMA, which indicates a potential rebound. However, the RSI is overbought, and the MRI indicates a Medium risk level. The earnings analysis shows a significant increase in revenue and profit margins in recent quarters. The analyst consensus is Buy, but the target price range is relatively wide, indicating some uncertainty around the stock's performance.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.